apc-conjugated anti-cd34 antibody Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Becton Dickinson apc conjugated anti cd34
    Apc Conjugated Anti Cd34, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc conjugated anti cd34/product/Becton Dickinson
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    apc conjugated anti cd34 - by Bioz Stars, 2021-05
    86/100 stars
      Buy from Supplier

    86
    Becton Dickinson allophycocyanin apc conjugated anti cd34
    Allophycocyanin Apc Conjugated Anti Cd34, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/allophycocyanin apc conjugated anti cd34/product/Becton Dickinson
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    allophycocyanin apc conjugated anti cd34 - by Bioz Stars, 2021-05
    86/100 stars
      Buy from Supplier

    86
    Becton Dickinson apc conjugated anti cd34 antibody
    Sample of selected flow cytometric plots for identification of circulating endothelial progenitor cells depending on pre-treatment counts in invasive breast cancer cases and in a healthy individual. Charts 1 and 1a demonstrate a profile of a subject free of breast cancer (control) with circulating endothelial progenitor cells (EPCs) count of 0.30 cells/µL. Charts 2 and 2a show an invasive breast cancer (IBrC) patient with T1a, N0, M0, grade = 2, tumour diameter = 0.5 cm, ER/PR+ and HER2-Ki-67 = 15%, a baseline number of circulating EPCs was 37.99 cells/µL. A patient after 40 months of follow-up is still alive. Charts 3 and 3a demonstrate an IBrC subject with T2, N0, M0, grade = 3, tumour diameter = 2.5 cm, ER+, PR−, HER2−; Ki-67 = 45%, a pre-treatment number of circulating EPCs was 4.32 cells/µL. A patient passed away due to lung, liver, and bones metastases. Quantification of circulating EPCs was made in a peripheral blood mononuclear cell (PBMC) fraction. A gating strategy for the identification of circulating EPCs by applying CD45-PerCP-Cy5.5, CD31-FITC (R2: CD45–/CD31+ gating to exclude lymphocytes), <t>CD34-APC,</t> and CD133-PE (R3: CD133+/CD34+ gating identifies endothelial progenitor cells) conjugated antibodies was used. The CD45 population was gated on the overall lymphocyte + monocyte cells in the PBMC. A detailed flow cytometry plots presentation was published in our previous study [ 9 ].
    Apc Conjugated Anti Cd34 Antibody, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc conjugated anti cd34 antibody/product/Becton Dickinson
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    apc conjugated anti cd34 antibody - by Bioz Stars, 2021-05
    86/100 stars
      Buy from Supplier

    95
    Becton Dickinson apc mouse anti human cd34
    Sample of selected flow cytometric plots for identification of circulating endothelial progenitor cells depending on pre-treatment counts in invasive breast cancer cases and in a healthy individual. Charts 1 and 1a demonstrate a profile of a subject free of breast cancer (control) with circulating endothelial progenitor cells (EPCs) count of 0.30 cells/µL. Charts 2 and 2a show an invasive breast cancer (IBrC) patient with T1a, N0, M0, grade = 2, tumour diameter = 0.5 cm, ER/PR+ and HER2-Ki-67 = 15%, a baseline number of circulating EPCs was 37.99 cells/µL. A patient after 40 months of follow-up is still alive. Charts 3 and 3a demonstrate an IBrC subject with T2, N0, M0, grade = 3, tumour diameter = 2.5 cm, ER+, PR−, HER2−; Ki-67 = 45%, a pre-treatment number of circulating EPCs was 4.32 cells/µL. A patient passed away due to lung, liver, and bones metastases. Quantification of circulating EPCs was made in a peripheral blood mononuclear cell (PBMC) fraction. A gating strategy for the identification of circulating EPCs by applying CD45-PerCP-Cy5.5, CD31-FITC (R2: CD45–/CD31+ gating to exclude lymphocytes), <t>CD34-APC,</t> and CD133-PE (R3: CD133+/CD34+ gating identifies endothelial progenitor cells) conjugated antibodies was used. The CD45 population was gated on the overall lymphocyte + monocyte cells in the PBMC. A detailed flow cytometry plots presentation was published in our previous study [ 9 ].
    Apc Mouse Anti Human Cd34, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc mouse anti human cd34/product/Becton Dickinson
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    apc mouse anti human cd34 - by Bioz Stars, 2021-05
    95/100 stars
      Buy from Supplier


    N/A
    The Mouse CD34 APC conjugated Antibody from R D Systems is a sheep polyclonal antibody to CD34 This antibody reacts with mouse The Mouse CD34 APC conjugated Antibody has been
      Buy from Supplier

    N/A
    The 4H11 monoclonal antibody reacts with human CD34 also known as mucosialin CD34 belongs to a protein family which also includes endoglycan and podocalyxin Members of this family are single
      Buy from Supplier

    N/A
    The Canine CD34 APC conjugated Antibody from R D Systems is a mouse monoclonal antibody to CD34 This antibody reacts with canine The Canine CD34 APC conjugated Antibody has been
      Buy from Supplier

    Image Search Results


    Sample of selected flow cytometric plots for identification of circulating endothelial progenitor cells depending on pre-treatment counts in invasive breast cancer cases and in a healthy individual. Charts 1 and 1a demonstrate a profile of a subject free of breast cancer (control) with circulating endothelial progenitor cells (EPCs) count of 0.30 cells/µL. Charts 2 and 2a show an invasive breast cancer (IBrC) patient with T1a, N0, M0, grade = 2, tumour diameter = 0.5 cm, ER/PR+ and HER2-Ki-67 = 15%, a baseline number of circulating EPCs was 37.99 cells/µL. A patient after 40 months of follow-up is still alive. Charts 3 and 3a demonstrate an IBrC subject with T2, N0, M0, grade = 3, tumour diameter = 2.5 cm, ER+, PR−, HER2−; Ki-67 = 45%, a pre-treatment number of circulating EPCs was 4.32 cells/µL. A patient passed away due to lung, liver, and bones metastases. Quantification of circulating EPCs was made in a peripheral blood mononuclear cell (PBMC) fraction. A gating strategy for the identification of circulating EPCs by applying CD45-PerCP-Cy5.5, CD31-FITC (R2: CD45–/CD31+ gating to exclude lymphocytes), CD34-APC, and CD133-PE (R3: CD133+/CD34+ gating identifies endothelial progenitor cells) conjugated antibodies was used. The CD45 population was gated on the overall lymphocyte + monocyte cells in the PBMC. A detailed flow cytometry plots presentation was published in our previous study [ 9 ].

    Journal: Journal of Clinical Medicine

    Article Title: Low Pre-Treatment Count of Circulating Endothelial Progenitors as a Prognostic Biomarker of the High Risk of Breast Cancer Recurrence

    doi: 10.3390/jcm8111984

    Figure Lengend Snippet: Sample of selected flow cytometric plots for identification of circulating endothelial progenitor cells depending on pre-treatment counts in invasive breast cancer cases and in a healthy individual. Charts 1 and 1a demonstrate a profile of a subject free of breast cancer (control) with circulating endothelial progenitor cells (EPCs) count of 0.30 cells/µL. Charts 2 and 2a show an invasive breast cancer (IBrC) patient with T1a, N0, M0, grade = 2, tumour diameter = 0.5 cm, ER/PR+ and HER2-Ki-67 = 15%, a baseline number of circulating EPCs was 37.99 cells/µL. A patient after 40 months of follow-up is still alive. Charts 3 and 3a demonstrate an IBrC subject with T2, N0, M0, grade = 3, tumour diameter = 2.5 cm, ER+, PR−, HER2−; Ki-67 = 45%, a pre-treatment number of circulating EPCs was 4.32 cells/µL. A patient passed away due to lung, liver, and bones metastases. Quantification of circulating EPCs was made in a peripheral blood mononuclear cell (PBMC) fraction. A gating strategy for the identification of circulating EPCs by applying CD45-PerCP-Cy5.5, CD31-FITC (R2: CD45–/CD31+ gating to exclude lymphocytes), CD34-APC, and CD133-PE (R3: CD133+/CD34+ gating identifies endothelial progenitor cells) conjugated antibodies was used. The CD45 population was gated on the overall lymphocyte + monocyte cells in the PBMC. A detailed flow cytometry plots presentation was published in our previous study [ 9 ].

    Article Snippet: For circulating EPCs enumeration, 50 µL of whole peripheral blood was incubated with a 10 μL fluorescein isothiocyanate (FITC)-conjugated anti-CD31, a 10 µL PerCP-Cy5.5-conjugated anti-CD45, as well as a 10 μL APC-conjugated anti-CD34 antibody (all BD Biosciences, Pharmingen, San Diego, CA, USA) and a 20 μL phycoerythrin (PE)-conjugated anti-CD133 antibody (Miltenyi Biotec, Bergisch Gladbach, Germany).

    Techniques: Flow Cytometry, Cytometry